Sam Haidar

2.4k total citations
21 papers, 972 citations indexed

About

Sam Haidar is a scholar working on Immunology, Statistics and Probability and Economics and Econometrics. According to data from OpenAlex, Sam Haidar has authored 21 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 6 papers in Statistics and Probability and 5 papers in Economics and Econometrics. Recurrent topics in Sam Haidar's work include Biosimilars and Bioanalytical Methods (8 papers), Statistical Methods in Clinical Trials (6 papers) and Pharmaceutical Economics and Policy (4 papers). Sam Haidar is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Statistical Methods in Clinical Trials (6 papers) and Pharmaceutical Economics and Policy (4 papers). Sam Haidar collaborates with scholars based in United States, Switzerland and Netherlands. Sam Haidar's co-authors include Dale P. Conner, Lawrence X. Yu, Barbara M. Davit, Patrick E. Nwakama, Donald J. Schuirmann, Fairouz Makhlouf, Yongsheng Yang, Janet Woodcock, Mei‐Ling Chen and Robert Lionberger and has published in prestigious journals such as Pharmaceutical Research, Journal of Pharmaceutical Sciences and Journal of Pharmaceutical and Biomedical Analysis.

In The Last Decade

Sam Haidar

20 papers receiving 935 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sam Haidar United States 14 292 274 265 174 148 21 972
Barbara M. Davit United States 20 470 1.6× 491 1.8× 376 1.4× 225 1.3× 530 3.6× 35 1.7k
André J. Jackson United States 19 61 0.2× 142 0.5× 213 0.8× 68 0.4× 106 0.7× 46 800
Kevin Krudys United States 11 77 0.3× 192 0.7× 116 0.4× 65 0.4× 42 0.3× 20 792
Patrick Marroum United States 17 58 0.2× 123 0.4× 99 0.4× 50 0.3× 295 2.0× 36 777
Ramana Uppoor United States 12 98 0.3× 185 0.7× 90 0.3× 31 0.2× 107 0.7× 26 531
L J Lesko United States 12 45 0.2× 162 0.6× 150 0.6× 51 0.3× 113 0.8× 21 956
Lisa J. Benincosa United States 14 98 0.3× 84 0.3× 161 0.6× 112 0.6× 15 0.1× 29 804
Efthymios Manolis Netherlands 12 76 0.3× 163 0.6× 115 0.4× 61 0.4× 16 0.1× 18 595
Marylore Chenel France 17 61 0.2× 144 0.5× 186 0.7× 78 0.4× 20 0.1× 52 975
R L Lalonde United States 8 139 0.5× 96 0.4× 226 0.9× 67 0.4× 12 0.1× 10 668

Countries citing papers authored by Sam Haidar

Since Specialization
Citations

This map shows the geographic impact of Sam Haidar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam Haidar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam Haidar more than expected).

Fields of papers citing papers by Sam Haidar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sam Haidar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam Haidar. The network helps show where Sam Haidar may publish in the future.

Co-authorship network of co-authors of Sam Haidar

This figure shows the co-authorship network connecting the top 25 collaborators of Sam Haidar. A scholar is included among the top collaborators of Sam Haidar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sam Haidar. Sam Haidar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Chongwoo, et al.. (2023). Lessons Learned from Regulatory Submissions Involving Endogenous Therapeutic Analyte Bioanalysis. Bioanalysis. 16(3). 171–184. 2 indexed citations
2.
Haidar, Sam, et al.. (2019). Evaluation of Stability Using One Versus Three Tubes for Each Quality Control Concentration in Matrix-Based Bioanalysis. Bioanalysis. 11(20). 1823–1834. 4 indexed citations
3.
4.
Haidar, Sam & Kara Scheibner. (2016). Bioanalytical Inspections: Organizational Changes and Regulatory Perspectives. Bioanalysis. 8(10). 999–1002. 1 indexed citations
5.
Haidar, Sam, Xinyuan Zhang, Wenlei Jiang, et al.. (2015). Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. Journal of Pharmaceutical Sciences. 105(2). 996–1005. 49 indexed citations
6.
Booth, Brian, Mark E. Arnold, Binodh DeSilva, et al.. (2014). Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance. The AAPS Journal. 17(2). 277–288. 86 indexed citations
7.
Li, Bing V., et al.. (2012). Common Reasons for “For-Cause” Inspections in Bioequivalence Studies Submitted to the Food and Drug Administration. The AAPS Journal. 15(1). 10–14. 1 indexed citations
8.
Davit, Barbara M., Mei‐Ling Chen, Dale P. Conner, et al.. (2012). Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration. The AAPS Journal. 14(4). 915–924. 85 indexed citations
9.
Garofolo, Fabio, Brian Booth, C.T. Viswanathan, et al.. (2012). Conference Report: Us Fda/Ema Harmonization of Their Bioanalytical Guidance/Guideline And Activities of The Global Bioanalytical Consortium. Bioanalysis. 4(3). 231–236. 15 indexed citations
10.
Tompkins, Leslie M., Caitlin Lynch, Sam Haidar, James E. Polli, & Hongbing Wang. (2010). Effects of Commonly Used Excipients on the Expression of CYP3A4 in Colon and Liver Cells. Pharmaceutical Research. 27(8). 1703–1712. 24 indexed citations
11.
Davit, Barbara M., Patrick E. Nwakama, Dale P. Conner, et al.. (2009). Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. Annals of Pharmacotherapy. 43(10). 1583–1597. 228 indexed citations
12.
Haidar, Sam, Fairouz Makhlouf, Donald J. Schuirmann, et al.. (2008). Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable Drugs. The AAPS Journal. 10(3). 450–454. 70 indexed citations
13.
Davit, Barbara M., Dale P. Conner, Sam Haidar, et al.. (2008). Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications. The AAPS Journal. 10(1). 148–156. 94 indexed citations
14.
Haidar, Sam, Fairouz Makhlouf, Donald J. Schuirmann, et al.. (2008). Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable Drugs. The AAPS Journal. 10(3). 480–480. 7 indexed citations
15.
Haidar, Sam, Barbara M. Davit, Mei‐Ling Chen, et al.. (2007). Bioequivalence Approaches for Highly Variable Drugs and Drug Products. Pharmaceutical Research. 25(1). 237–241. 142 indexed citations
16.
Haidar, Sam, Steven B. Johnson, Michael J. Fossler, & Ajaz Hussain. (2002). Modeling the Pharmacokinetics and Pharmacodynamics of a Unique Oral Hypoglycemic Agent Using Neural Networks. Pharmaceutical Research. 19(1). 87–91. 21 indexed citations
17.
El‐Kattan, Ayman, C. S. Asbill, & Sam Haidar. (2000). Transdermal testing: practical aspects and methods. PubMed. 3(12). 426–430. 19 indexed citations
18.
Haidar, Sam, et al.. (1997). Evaluating a Possible Pharmacokinetic Interaction between Remifentanil and Esmolol in the Rat. Journal of Pharmaceutical Sciences. 86(11). 1278–1282. 25 indexed citations
19.
Haidar, Sam, et al.. (1997). The Pharmacokinetics and Electroencephalogram Response of Remifentanil Alone and in Combination with Esmolol in the Rat. Pharmaceutical Research. 14(12). 1817–1823. 13 indexed citations
20.
Yuen, Geoffrey J., David M. Morris, Patricia K. Mydlow, et al.. (1995). Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine. The Journal of Clinical Pharmacology. 35(12). 1174–1180. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara M. Davit Breakdown of academic impact, for papers by André J. Jackson Breakdown of academic impact, for papers by Kevin Krudys Breakdown of academic impact, for papers by Patrick Marroum Breakdown of academic impact, for papers by Ramana Uppoor Breakdown of academic impact, for papers by L J Lesko Breakdown of academic impact, for papers by Lisa J. Benincosa Breakdown of academic impact, for papers by Efthymios Manolis Breakdown of academic impact, for papers by Marylore Chenel Breakdown of academic impact, for papers by R L Lalonde
Rankless by CCL
2026